会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明授权
    • Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
    • 可用作凝血酶受体拮抗剂的取代的三环烟肼衍生物
    • US07037920B2
    • 2006-05-02
    • US10271715
    • 2002-10-16
    • Samuel ChackalamannilMariappan V. ChelliahMartin C. ClasbyYan Xia
    • Samuel ChackalamannilMariappan V. ChelliahMartin C. ClasbyYan Xia
    • A61K31/4355C07D515/04
    • C07D491/04C07D493/04C07D495/04
    • Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salts thereof, wherein: n1 and n2 are independently 0-2; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is alkyl or optionally substituted alkenyl; R22 is —COR23 or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative; R23 is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or —COOH and/or —SO3H substituted alkyl; R1, R2, R3, R9, R10 and R11 are as defined in the specification; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.
    • 具有下式的杂环取代的三环或其药学上可接受的盐,其中:n 1和n 2个独立地为0-2; Het是任选取代的单,双或三环杂芳族基团; B是烷基或任选取代的烯基; R 22是-COR 23或羧基,亚磺酰基,磺酰基,磺酰胺或氨基酸衍生物; R 23是卤代烷基; 烯基; 卤代烯基 炔基; 任选取代的环烷基; 环烷基 - 烷基; 芳基; 芳烷基 杂芳基; 杂环烷基; 或-COOH和/或-SO 3 H取代的烷基; R 1,R 2,R 3,R 9,R 10和R 9, R 11如本说明书中所定义; 以及含有它们的药物组合物以及通过施用所述化合物治疗与血栓形成,动脉粥样硬化,再狭窄,高血压,心绞痛,心律失常,心力衰竭和癌症相关的疾病的方法。
    • 17. 发明申请
    • Fused Ring Thrombin Receptor Antagonists
    • 融合环凝血酶受体拮抗剂
    • US20070244163A1
    • 2007-10-18
    • US11734057
    • 2007-04-11
    • Yan XiaMariappan V. ChelliahSamuel Chackalamannil
    • Yan XiaMariappan V. ChelliahSamuel Chackalamannil
    • A61K31/4439C07D491/02
    • C07D405/06C07D498/04
    • Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
    • 熔融环,具有下式的杂环取代的三环或所述化合物的药学上可接受的盐或溶剂合物,异构体或外消旋混合物,其中表示可选的双键,并且其中A N,N, M,N,N,N,N,N,N,N,N, R 8,R 9,R 10,R 11,R 32,R 12, 本文中定义了R32,X,Y,B和Het,其余取代基如说明书中所定义,以及含有它们的药物组合物和 通过施用所述化合物治疗与血栓形成,动脉粥样硬化,再狭窄,高血压,心绞痛,心律失常,心力衰竭和癌症相关的疾病。 还要求与其它心血管药物联合治疗。